The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000314.8(PTEN):c.64G>T (p.Asp22Tyr)

CA377782011

468706 (ClinVar)

Gene: PTEN (HGNC:5728)
Condition: PTEN hamartoma tumor syndrome (MONDO:0017623)
Inheritance Mode: Autosomal dominant inheritance
UUID: 367476c0-29fd-418a-be77-1340085d066d
Approved on: 2026-06-16
Published on: 2026-06-26

HGVS expressions

NM_000314.8:c.64G>T
NM_000314.8(PTEN):c.64G>T (p.Asp22Tyr)
NC_000010.11:g.87864533G>T
CM000672.2:g.87864533G>T
NC_000010.10:g.89624290G>T
CM000672.1:g.89624290G>T
NC_000010.9:g.89614270G>T
NG_007466.2:g.6095G>T
NG_033079.1:g.3905C>A
ENST00000700029.2:c.64G>T
ENST00000710265.1:c.64G>T
ENST00000472832.3:c.64G>T
ENST00000688922.2:c.64G>T
ENST00000700021.1:c.64G>T
ENST00000700022.1:c.64G>T
ENST00000706954.1:c.64G>T
ENST00000706955.1:c.64G>T
ENST00000686459.1:c.64G>T
ENST00000688158.1:c.64G>T
ENST00000688308.1:c.64G>T
ENST00000693560.1:c.583G>T
ENST00000371953.8:c.64G>T
ENST00000371953.7:c.64G>T
ENST00000462694.1:n.66G>T
ENST00000487939.1:n.85G>T
ENST00000610634.1:c.-39G>T
ENST00000618586.1:n.33G>T
NM_000314.5:c.64G>T
NM_000314.6:c.64G>T
NM_001304717.2:c.583G>T
NM_001304718.1:c.-642G>T
NM_000314.7:c.64G>T
NM_001304717.5:c.583G>T
NM_001304718.2:c.-642G>T
More

Likely Pathogenic

Met criteria codes 5
PM2_Supporting PP3 PP2 PS2 PM5

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PTEN Version 3.2.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
PTEN VCEP
PTEN c.64G>T (p.Asp22Tyr) meets criteria to be classified as Likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.2.0). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (internal laboratory contributor SCV003923984.2). PM5: Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic and with equal or lesser BLOSUM62 score has been seen before (ClinVar Variation ID 233456, SCV004183305.1). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PP3: REVEL score > 0.7 (score of this variant = 0.957) PM2_supporting: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).
Met criteria codes
PM2_Supporting
Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).
PP3
REVEL score > 0.7 (score of this variant = 0.957)
PP2
PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
PS2
De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (internal laboratory contributor SCV003923984.2).
PM5
Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic and with equal or lesser BLOSUM62 score has been seen before (ClinVar Variation ID 233456, SCV004183305.1).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.